Joachim Rudolph

This paper identifies ATF6α as a non-transcriptional regulator of peroxisome quality control through its interaction with ABCD3, and shows how this interaction can be modulated by Ceapin to influence cancer-related processes.

This paper identifies a potent and specific SMARCA2/A4 degrader, G-6599, which works via FBXO22 recruitment and covalent conjugation, offering therapeutic potential.

This study identifies a nonenzymatic role of IRE1 in cancer cell cycle progression and tumor growth, independent of its kinase-RNase activity.

This study shows that disrupting IRE1α's kinase domain reduces multiple myeloma tumor growth and enhances treatment efficacy, suggesting it as a therapeutic target.